Healthcare Distribution Alliance – Patients Move Us.
Share Print
blog banner

HDA Blog

Traceability Blog Entries

Davis Spotlights HDA's 2021 Strategic Priorities

Posted

HDA will be carrying forward the early lessons learned from COVID-19 pandemic and supporting response efforts in 2021, writes President and CEO Chip Davis in the January 4 issue of Chain Drug Review — particularly as distributors play a role in the largest public vaccination effort in recent memory. Davis provided his perspective on the year ahead, along with other healthcare trade association leaders, as part of the publication’s 2021 “Pharmacy Outlook” feature.

Read more...

DSCSA, the 2023 Requirements and EPCIS

Posted by Anita T. Ducca

Since the enactment of the Drug Supply Chain Security Act in 2013, members of the pharmaceutical supply chain have undertaken efforts to meet each of the major milestones contained within the statute’s 10-year timeline to further secure the safety of the products being distributed. The industry’s progress to 2023 interoperability was top of mind as supply chain and other stakeholders came together at HDA’s recent Traceability Online Seminar.

Read more...

Verification Network Update: Less than 60 Days Remain

Posted by Justine Freisleben

Industry and service providers continue to work to implement the Drug Supply Chain Security Act’s (DSCSA) serialized saleable return milestone. With the end of FDA-granted enforcement discretion ending on November 27, 2020, and the industry simultaneously responding to COVID-19, it is all hands on deck to reach the compliance finish line.

Read more...

HDA “Year in Review” Spotlights 2019 Accomplishments

Posted

HDA has published “A Year in Review,” which chronicles the Alliance’s 2019 activities. Highlighted accomplishments include:

Read more...

HDA Highlights Distributors' Value, 2020 Policy Outlook in Chain Drug Review

Posted

With 2020 underway, HDA’s John M. Gray provided perspective on the vital role of pharmaceutical distributors and the Alliance’s policy priorities as part of Chain Drug Review’s annual “Pharmacy Outlook” feature.

Read more...
View more
© 2020 Healthcare Distribution Alliance. All rights reserved.
HDA: E | C | C2 | NF | O365